Partially hidden markov model for time-varying principal stratification in HIV prevention trials

Journal of the American Statistical Association

Volumn 107, Issue 497, 2012, Pages 52-65

  Dai, James Y ^a   Gilbert, Peter B ^a   Mâsse, Benoît R ^a,b  

^a USA   (United States)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Causal inference; Direct effect; Microbicide; Post treatment variables

Indexed keywords

EID: 84862841846     PISSN: 01621459     EISSN: None     Source Type: Journal    
DOI: 10.1080/01621459.2011.643743     Document Type: Article

References (48)

1. Albert, P. S. (1991), "A Two-State Markov Mixture Model From a Time Series of Epileptic Seizure Counts," Biometrics, 47, 1371-1381. [61]
2. Altman, R. M., and Petkau, A. J. (2005), "Application of Hidden Markov Models to Multiple Sclerosis Lesion Count Data," Statistics in Medicine, 24, 2335-2344. [54]
3. Angrist, J. D., Imbens, G.W., and Rubin, D. B. (1996), "Identification of Causal Effects Using Instrumental Variables," Journal of the American Statistical Association, 91, 444-455. [54,55]
4. Baum, L. E., and Petrie, T. (1966), "Statistical Inferences for Probabilistic Functions of Finite State Markov Chains," The Annals of Mathematical Statistics, 37, 1554-1563. [58,59]
5. Baum, L. E., Petrie, T., Soules, G., and Weiss, N. (1970), "A Maximization Technique Occurring in the Statistical Analysis of Probabilistic Functions of Markov Chains," The Annals of Mathematical Statistics, 41, 164-171. [59]
6. Bickel, P. J., Ritov, Y., and Rydén, T. (1998), "Asymptotic Normality of the Maximum-likelihood Estimator for General Hidden Markov Models," The Annals of Statistics, 26, 1614-1635. [58]
7. Capppe, O., Moulines, E., and Ryden, T. (2005), Inference in Hidden Markov Models, New York: Springer. [63]
8. Cassel, M. M., Halperin, D. T., Shelton, J. D., and Stanton, D. (2006), "Risk Compensation: The Achilles' Heel of Innovations in HIV Prevention," British Medical Journal, 332, 605-607. [52]
9. Celum, C., Wald, A., Hughes, J., Sanchez, J., Stewart, R., Delany-Moretlwe, S., Cowan, F., Casapia, M., Ortiz, A., Fuchs, J., Buchbinder, S., Koblin, B., Zwerski, S., Rose, S., Wang, J., Corey, L., and the HPTN 039 Protocol Team (2008), "Effect of Aciclovir on HIV-1 Acquisition in Herpes Simplex Virus 2 Seropositive Women and Men Who Have Sex With Men: A Randomised Double-Blind, Placebo-Controlled Trial," Lancet, 371, 2109-2119. [57]
10. Centers for Disease Control. (1993), "Update: Barrier Protection Against HIV Infection and Other Sexually Transmitted Diseases," Morbidity and Mortality Weekly Report, 42, 589-597. [52]
11. Cox, D. R. (1958), Planning of Experiments, New York: Wiley. [55]
12. Cox, D. R., and Hinkley, D. V. (1974), Theoretical Statistics, New York: Chapman & Hall. [58]
13. Crepaz, N., Hart, T. A., and Marks, G. (2004), "Highly Active Antiretroviral Therapy and Sexual Risk Behavior: A Meta-Analytic Review," Journal of American Medical Association, 292, 224-236. [55]
14. Elias, C. J., and Coggins, C. (1996), "Female Controlled Method to Prevent Sexual Transmission of HIV," AIDS, 10, S43-S51. [52]
15. Fleming, T. R., and Richardson, B. A. (2004), "Some Design Issues in Trials of Microbicides for the Prevention of HIV Infection," Journal of Infectious Diseases, 190, 666-674. [52]
16. Frangakis, C. E., Brookmeyer, R. S.,Varadhan, R., Safaeian, M., Vlahov, D., and Strathdee, S. A. (2004), "Methodology for Evaluating a Partially Controlled Longitudinal Treatment Using Principal Stratification,With Application to a Needle Exchange Program," Journal of the American Statistical Association, 99, 239-249. [54]
17. Frangakis, C. E., and Rubin, D. B. (2002), "Principal Stratification in Causal Inference," Biometrics, 58, 21-29. [54,55]
18. Gilbert, P. B., Bosch, R. J., and Hudgens, M. G. (2003), "Sensitivity Analysis for the Assessment of Causal Vaccine Effects on Viral Load in HIV Vaccine Trials," Biometrics, 59, 531-541. [54]
19. Grant, R. M., Lama, J. R. L. A. P., McMahan, V., Liu, A. Y., Vargas, L., Giocochea, P., and the iPrEx Study Team (2010), "Preexposure Chemoprophlaxis for HIV Prevention in Men Who Have SexWith Men," The New England Journal of Medicine, 363, 2587-2599. [57,62]
20. Halperin, D. (2007), What Do Gay Men Want?: An Essay on Sex, Risk and Subjectivity, Ann Arbor, MI: University of Michigan Press. [53]
21. Hernan, M. A., Brumback, B., and Robins, J. M. (2001), "Marginal Structural Models to Estimate the Joint Causal Effect of Nonrandomized Treatments," Journal of the American Statistical Association, 96, 440-448. [53,57]
22. Holland, P.W. (1986), "Statistics andCausal Inference," Journal of the American Statistical Association, 81, 945-960. [53]
23. Hughes, J. P., and Guttorp, P. (1994), "A Class of Stochastic Models for Relating Synoptic Atmospheric Patterns to Regional Hydrologic Phenomena," Water Resource Research, 30, 1535-1546. [61]
24. Imbens, G.W., and Rubin, D. B. (1997), "Bayesian Inference for Causal Effects in Randomized ExperimentsWith Noncompliance," The Annals of Statistics, 25, 305-327. [54,55,61]
25. Joffe, M. M., and Greene, T. (2009), "Related Causal Frameworks for Surrogate Outcomes," Biometrics, 65, 530-538. [53,54]
26. Kalbfleisch, J. D., and Prentice, R. L. (2002), The Statistical Analysis of Failure Time Data, Hoboken, NJ: Wiley. [57]
27. Karim, A. S., Richardson, B. A., Ramjee, G., Hoffman, I. F., Chirenje, M. Z., Taha, T., Kapina, M., Maslankowski, L., Coletti, A., Profy, A., Moench, T. R., Piwowar-Manning, E., Masse, B., Hillier, S. L., and Soto-Torres, L. (2011), "Safety and Effectiveness of Vaginal Microbicides BufferGel and 0.5% PRO 2000/5 Gel for the Prevention of HIV Infection in Women," AIDS, 25, 957-966. [52]
28. Lander, E. S., and Green, P. (1987), "Construction of Multilocus Genetic Linkage Maps in Humans," Proceedings of the National Academy of Sciences of the United States of America, 84, 2363-2367. [54]
29. Leroux, B. G. (1992), "Maximum-Likelihood Estimation for Hidden Markov Models," Stochastic Process and Their Applications, 40, 127-143. [54,58,61]
30. Lin, J. Y., Ten Have, T. R., and Elliott, M. R. (2008), "Longitudinal Nested Compliance Class Model in the Presence of Time-Varying Noncompliance," Journal of the American Statistical Association, 103, 462-473. [54,56,61]
31. Lin, J. Y., Ten Have, T. R., and Elliott, M. R. (2009), "Nested Markov Compliance Class Model in the Presence of Time-Varying Noncompliance," Biometrics, 65, 505-513. [54,61]
32. Neyman, J. (1923), "On the Application of Probability Theory to Agricultural Experiments: Essay on Principles, Section 9," Statistical Science, 5, 465-480 (translated in 1990). [53]
33. Petersen, M. L., Sinisi, S. E., and van der Laan, M. (2006), "Estimation of Direct Causal Effect," Epidemiology, 17, 276-284. [53]
34. Petrie, T. (1969), "Probabilistic Functions of Finite State Markov Chains," The Annals of Mathematical Statistics, 40, 97-115. [62]
35. Rabiner, L. R. (1989), "A Tutorial on Hidden Markov Models and Selected Applications in Speech Recognition," Proceedings of IEEE, 77, 257-284. [54]
36. Reid, S. E., Dai, J. Y., Wang, J., Sichalwe, B. N., Alkpomiemie, G., Cowan, F. M., Delany-Moretlwe, S., Baeten, J. M., Jughes, J. P., Wald, A., and Celum, C. (2010), "Pregnancy, Contraceptive Use and HIV Acquisition in HPTN 039: Relevance for HIV Prevention Trials Among African Women," Journal of Acquired Immune Deficiency Syndrome, 53, 606-613. [57]
37. Robins, J., and Greenland, S. (1992), "Identifiability and Exchangeability for Direct and Indirect Effect," Epidemiology, 3, 143-155. [53]
38. Robins, J. M., Hernan, M. A., and Brumback, B. (2000), "Marginal Structural Models andCausal Inference in Epidemiology," Epidemiology, 11, 550-560. [53]
39. Robins, J.M., Rotnitzky, A., and Scharfstein, D.O. (2000), "Sensitivity Analysis for SelectionBias andUnmeasured Confounding in Missing Data andCausal Inference Models," in Statistical Models in Epidemiology, eds. E. Halloran and D. Berry, New York: Spinger-Verlag, pp. 1-92. [53]
40. Rosenbaum, P. R. (1984), "The Consequences of Adjustment for a Concomitant Variable That Has Been Affected by Treatment," Journal of the Royal Statistical Society, Series A, 47, 656-666. [53]
41. Rosenblum, M., Jewell, N. P., van der Laan, M., Shiboski, S., van der Straten, A., and Padian, N. (2009), "Analysing Direct Effects in Randomized Trials With Secondary Interventions:AnApplication toHuman Immunodeficiency Virus Prevention Trials," Journal of the Royal Statistical Society, Series A, 172, 443-465. [52,53]
42. Rubin, D. B. (1978), "Bayesian Inference for Causal Effects: The Role of Randomization," The Annals of Statistics, 6, 34-58. [53,55]
43. Rubin, D. B (2004), "Direct and Indirect Effects Via Potential Outcomes," Scandinavian Journal of Statistics, 31, 161-170. [54]
44. Scott, S. L., James, G. M., and Sugar, C. A. (2005), "Hidden Markov Models for LongitudinalComparisons," Journal of American Statistical Association, 100, 359-369. [54]
45. Shirley, K. E., Small, D. S., Lynch, K. G., Maisto, S. A., and Oslin, D.W. (2010), "Hidden Markov Models for Alcoholism Treatment Trial Data," Annals of Applied Statistics, 3, 491-520. [54]
46. Stone, A. B., and Hitchcock, P. J. (1994), "Vaginal Microbicides for Preventing the Sexual Transmission of HIV," AIDS, 8, S285-S293. [52]
47. van der Laan, M., and Robins, J. M. (2003), Unified Methods for Censored Longitudinal Data and Causality, Cambridge: Springer-Verlag. [53]
48. Yuan, M., and Kendziorski, C. (2006), "Hidden MarkovModels forMicroarray Time Course Data in Multiple Biological Condition," Journal of American Statistical Association, 101, 1323-1340. [54]